JUBBONTI (denosumab-bbdz)
Jubbonti (denosumab-bbdz) is a RANK ligand inhibitor indicated to treat osteoporosis and increase bone mass in patients at high risk for fracture. It is used for postmenopausal women and men with osteoporosis, as well as individuals with glucocorticoid-induced osteoporosis. Additionally, the medication is approved for patients receiving specific cancer treatments, including men undergoing androgen deprivation therapy for nonmetastatic prostate cancer and women receiving adjuvant aromatase inhibitor therapy for breast cancer.
How JUBBONTI Works
Jubbonti works by binding to RANKL, a protein essential for the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. By blocking RANKL from interacting with its receptor, RANK, the drug inhibits the activity of these bone-destroying cells. This process decreases bone resorption and leads to an increase in bone mass and strength in both cortical and trabecular bone.
Details
- Status
- Prescription
- First Approved
- 2024-03-05
- Patent Cliff
- 2025
- Routes
- SUBCUTANEOUS
- Dosage Forms
- INJECTABLE
JUBBONTI Approval History
What JUBBONTI Treats
4 indicationsJUBBONTI is approved for 4 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Osteoporosis
- Glucocorticoid-Induced Osteoporosis
- Prostate Cancer
- Breast Cancer
JUBBONTI Boxed Warning
SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE • Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions ( 5.1 )] . • The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly in...
WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE • Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions ( 5.1 )] . • The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions ( 5.1 )] . • Prior to initiating Jubbonti in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Jubbonti in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.1 )]. WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. • Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported ( 5.1 ) . • The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia ( 5.1 ) . • Prior to initiating Jubbonti in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Jubbonti in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD ( 2.2 , 5.1 ) .
Pharmacists can substitute JUBBONTI for Prolia without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
JUBBONTI Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in JUBBONTI's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications JUBBONTI treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to JUBBONTI
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
JUBBONTI FDA Label Details
Indications & Usage
FDA Label (PDF)JUBBONTI is indicated for the treatment of Osteoporosis; Glucocorticoid-Induced Osteoporosis; Prostate Cancer; Breast Cancer.
WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE • Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resul...
Track JUBBONTI with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.